Literature DB >> 8813750

Seizures in dogs.

M Podell1.   

Abstract

Epileptic seizures are the most common neurologic problem of the dog. The ability of a clinician to start proper management does not require elaborate equipment or specialized skills. What is needed is a thorough assessment of the history and examination findings. Dogs with a history of seizures at less than 1 or greater than 7 years of age, a history of behavioral changes, an initial interictal interval of less than 4 weeks, or an initial partial seizure should be suspected of having an identifiable underlying cause for the seizures. As such, an appropriate diagnostic evaluation should be done. Once a cause has been determined, PB is the AED of choice for dogs without underlying liver disease. Factors that enhance successful PB therapy are early initiation of therapy and proper monitoring of trough serum concentrations. Dogs that develop functional tolerance to PB should be given oral potassium bromide as the second AED. Diazepam per rectum can be used as an at-home therapy to stop cluster seizure activity. Overall, improved seizure control can be achieved by establishing a well-thought out therapeutic monitoring schedule. This approach will lead to improved quality of life for the patient, resulting in greater client satisfaction and less clinician frustration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813750

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  9 in total

1.  Clinical Risk Factors for Early Seizure Recurrence in Dogs Hospitalized for Seizure Evaluation.

Authors:  M Kwiatkowska; A Tipold; E Huenerfauth; A Pomianowski
Journal:  J Vet Intern Med       Date:  2018-02-18       Impact factor: 3.333

Review 2.  Treatment in canine epilepsy--a systematic review.

Authors:  Marios Charalambous; David Brodbelt; Holger A Volk
Journal:  BMC Vet Res       Date:  2014-10-22       Impact factor: 2.741

3.  Seizure disorders in 43 cattle.

Authors:  A D'Angelo; C Bellino; I Bertone; G Cagnotti; B Iulini; B Miniscalco; C Casalone; P Gianella; A Cagnasso
Journal:  J Vet Intern Med       Date:  2015-04-09       Impact factor: 3.333

4.  Retrospective epidemiological study of canine epilepsy in Japan using the International Veterinary Epilepsy Task Force classification 2015 (2003-2013): etiological distribution, risk factors, survival time, and lifespan.

Authors:  Yuji Hamamoto; Daisuke Hasegawa; Shunta Mizoguchi; Yoshihiko Yu; Masae Wada; Takayuki Kuwabara; Aki Fujiwara-Igarashi; Michio Fujita
Journal:  BMC Vet Res       Date:  2016-11-09       Impact factor: 2.741

5.  Intranasal Midazolam versus Rectal Diazepam for the Management of Canine Status Epilepticus: A Multicenter Randomized Parallel-Group Clinical Trial.

Authors:  M Charalambous; S F M Bhatti; L Van Ham; S Platt; N D Jeffery; A Tipold; J Siedenburg; H A Volk; D Hasegawa; A Gallucci; G Gandini; M Musteata; E Ives; A E Vanhaesebrouck
Journal:  J Vet Intern Med       Date:  2017-05-24       Impact factor: 3.333

6.  Effects of long-term phenobarbital treatment on the liver in dogs.

Authors:  P B Müller; J Taboada; G Hosgood; B P Partington; J L VanSteenhouse; H W Taylor; K J Wolfsheimer
Journal:  J Vet Intern Med       Date:  2000 Mar-Apr       Impact factor: 3.333

7.  Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs.

Authors:  Marion Bankstahl; Jens P Bankstahl; Wolfgang Löscher
Journal:  BMC Vet Res       Date:  2013-10-09       Impact factor: 2.741

Review 8.  Seizures in horses: diagnosis and classification.

Authors:  Véronique A Lacombe
Journal:  Vet Med (Auckl)       Date:  2015-10-05

9.  Continuous rate infusion of midazolam as emergent treatment for seizures in dogs.

Authors:  Kathryn Y Bray; Christopher L Mariani; Peter J Early; Karen R Muñana; Natasha J Olby
Journal:  J Vet Intern Med       Date:  2020-12-16       Impact factor: 3.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.